|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mari E, Floriani I, Tinazzi A, et al:
Efficacy of adjuvant chemotherapy after curative resection for
gastric cancer: a meta-analysis of published randomised trials. A
study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi
dell’Apparato Digerente). Ann Oncol. 11:837–843. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: the role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sijbers AM, de Laat WL, Ariza RR, et al:
Xeroderma pigmentosum group F caused by a defect in a
structure-specific DNA repair endonuclease. Cell. 86:811–822. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friboulet L, Olaussen KA, Pignon JP, et
al: ERCC1 isoform expression and DNA repair in non-small-cell lung
cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen WW, Wang F and Xu RH: Platinum-based
versus non-platinum-based chemotherapy as first line treatment of
inoperable, advanced gastric adenocarcinoma: a meta-analysis. PLoS
One. 8:e689742013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Richards D, McCollum D, Wilfong L, et al:
Phase II trial of docetaxel and oxaliplatin in patients with
advanced gastric cancer and/or adenocarcinoma of the
gastroesophageal junction. Ann Oncol. 19:104–108. 2008. View Article : Google Scholar
|
|
8
|
Yamada Y, Boku N, Nishina T, et al: Impact
of excision repair cross-complementing gene 1 (ERCC1) on the
outcomes of patients with advanced gastric cancer: correlative
study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol.
24:2560–2565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wei J, Zou Z, Qian X, et al: ERCC1 mRNA
levels and survival of advanced gastric cancer patients treated
with a modified FOLFOX regimen. Br J Cancer. 98:1398–1402. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsubara J, Nishina T, Yamada Y, et al:
Impacts of excision repair cross-complementing gene 1 (ERCC1),
dihydropyrimidine dehydrogenase, and epidermal growth factor
receptor on the outcomes of patients with advanced gastric cancer.
Br J Cancer. 98:832–839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Graeff P, Crijns AP, de Jong S, et al:
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial
ovarian cancer: a meta-analysis. Br J Cancer. 101:149–159. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gooden MJ, de Bock GH, Leffers N, Daemen T
and Nijman HW: The prognostic influence of tumour-infiltrating
lymphocytes in cancer: a systematic review with meta-analysis. Br J
Cancer. 105:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baek SK, Kim SY, Lee JJ, Kim YW, Yoon HJ
and Cho KS: Increased ERCC expression correlates with improved
outcome of patients treated with cisplatin as an adjuvant therapy
for curatively resected gastric cancer. Cancer Res Treat. 38:19–24.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bamias A, Karina M, Papakostas P, et al: A
randomized phase III study of adjuvant platinum/docetaxel
chemotherapy with or without radiation therapy in patients with
gastric cancer. Cancer Chemother Pharmacol. 65:1009–1021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
De Dosso S, Zanellato E, Nucifora M, et
al: ERCC1 predicts outcome in patients with gastric cancer treated
with adjuvant cisplatin-based chemotherapy. Cancer Chemother
Pharmacol. 72:159–165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fareed KR, Al-Attar A, Soomro IN, et al:
Tumour regression and ERCC1 nuclear protein expression predict
clinical outcome in patients with gastro-oesophageal cancer treated
with neoadjuvant chemotherapy. Br J Cancer. 102:1600–1607. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang ZH, Hua D, Du X, et al: ERCC1
polymorphism, expression and clinical outcome of oxaliplatin-based
adjuvant chemotherapy in gastric cancer. World J Gastroenterol.
14:6401–6407. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim JS, Kim MA, Kim TM, et al: Biomarker
analysis in stage III–IV (M0) gastric cancer patients who received
curative surgery followed by adjuvant 5-fluorouracil and cisplatin
chemotherapy: epidermal growth factor receptor (EGFR) associated
with favourable survival. Br J Cancer. 100:732–738. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim KH, Kwon HC, Oh SY, et al:
Clinicopathologic significance of ERCC1, thymidylate synthase and
glutathione S-transferase P1 expression for advanced gastric cancer
patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Biomarkers. 16:74–82. 2011. View Article : Google Scholar
|
|
22
|
Kwon HC, Roh MS, Oh SY, et al: Prognostic
value of expression of ERCC1, thymidylate synthase, and glutathione
S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in
advanced gastric cancer. Ann Oncol. 18:504–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu YP, Ling Y, Qi QF, et al: The effects
of ERCC1 expression levels on the chemosensitivity of gastric
cancer cells to platinum agents and survival in gastric cancer
patients treated with oxaliplatin-based adjuvant chemotherapy.
Oncol Lett. 5:935–942. 2013.PubMed/NCBI
|
|
24
|
Ozkan M, Akbudak IH, Deniz K, et al:
Prognostic value of excision repair cross-complementing gene 1
expression for cisplatin-based chemotherapy in advanced gastric
cancer. Asian Pac J Cancer Prev. 11:181–185. 2010.PubMed/NCBI
|
|
25
|
Qi YJ, Cui S, Yang YZ, et al: Excision
repair cross-complementation group 1 codon 118 polymorphism, micro
ribonucleic acid and protein expression, clinical outcome of the
advanced gastric cancer response to first-line FOLFOX-4 in
Qinghai-Tibetan plateau population. J Cancer Res Ther. 9:410–415.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Squires MH III, Fisher SB, Fisher KE, et
al: Differential expression and prognostic value of ERCC1 and
thymidylate synthase in resected gastric adenocarcinoma. Cancer.
119:3242–3250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen S, Zhang J, Wang R, Luo X and Chen H:
The platinum-based treatments for advanced non-small cell lung
cancer, is low/negative ERCC1 expression better than high/positive
ERCC1 expression? A meta-analysis. Lung Cancer. 70:63–70. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li S, Wu J, Chen Y, et al: ERCC1
expression levels predict the outcome of platinum-based
chemotherapies in advanced bladder cancer: a meta-analysis.
Anticancer Drugs. 25:106–114. 2014. View Article : Google Scholar
|
|
29
|
Huang MY, Tsai HL, Lin CH, et al:
Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for
stage III colorectal cancer patients receiving FOLFOX-4 adjuvant
chemotherapy. J Surg Oncol. 108:457–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gerhard R, Carvalho A, Carneiro V, et al:
Clinicopathological significance of ERCC1 expression in breast
cancer. Pathol Res Pract. 209:331–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin M, Yan J, Martinez-Balibrea E, et al:
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of
oxaliplatin-based chemotherapies in gastric and colorectal cancer:
a systemic review and meta-analysis. Clin Cancer Res. 17:1632–1640.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parker RJ, Eastman A, Bostick-Bruton F and
Reed E: Acquired cisplatin resistance in human ovarian cancer cells
is associated with enhanced repair of cisplatin-DNA lesions and
reduced drug accumulation. J Clin Invest. 87:772–777. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Satoh A, Toyota M, Itoh F, et al:
Epigenetic inactivation of CHFR and sensitivity to microtubule
inhibitors in gastric cancer. Cancer Res. 63:8606–8613.
2003.PubMed/NCBI
|
|
34
|
Chen HY, Shao CJ, Chen FR, Kwan AL and
Chen ZP: Role of ERCC1 promoter hypermethylation in drug resistance
to cisplatin in human gliomas. Int J Cancer. 126:1944–1954.
2010.
|
